Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
The next unit of science: Is the scientific paper due to be replaced?
Artificial intelligence is pushing scientific publishing to the brink. For a field as sprawling as neuroscience, the crisis may also be an opportunity to finally connect findings across subfields.
The next unit of science: Is the scientific paper due to be replaced?
Artificial intelligence is pushing scientific publishing to the brink. For a field as sprawling as neuroscience, the crisis may also be an opportunity to finally connect findings across subfields.
Funding crisis in Argentina sparks new wave of protests
Two years after the country’s research funding collapsed, scientists are demonstrating against the government’s failure to restore previously cut scholarships and increase salaries as required by a 2025 law.
Funding crisis in Argentina sparks new wave of protests
Two years after the country’s research funding collapsed, scientists are demonstrating against the government’s failure to restore previously cut scholarships and increase salaries as required by a 2025 law.
‘Slightly unhinged’ federal autism meeting portends unclear research priorities
The meeting last week sparked concerns about the latest Interagency Autism Coordinating Committee’s ability to perform its core function: developing a strategy to support autism research.
‘Slightly unhinged’ federal autism meeting portends unclear research priorities
The meeting last week sparked concerns about the latest Interagency Autism Coordinating Committee’s ability to perform its core function: developing a strategy to support autism research.